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Recently, it has been shown that silver nanoparticles (AgNPs) provide a unique approach to the treatment of
tumors, especially those of neuroepithelial origin. Thus, the aim of this study was to evaluate the impact of AgNPs
on proliferation and activation of the intrinsic apoptotic pathway of glioblastoma multiforme (GBM) cells cultured in
an in ovo model. Human GBM cells, line U-87, were placed on chicken embryo chorioallantoic membrane. After
8 days, the tumors were divided into three groups: control (non-treated), treated with colloidal AgNPs (40 μg/ml),
and placebo (tumors supplemented with vehicle only). At the end of the experiment, all tumors were isolated.
Assessment of cell proliferation and cell apoptosis was estimated by histological, immunohistochemical, and
Western blot analyses. The results show that AgNPs can influence GBM growth. AgNPs inhibit proliferation of GBM
cells and seem to have proapoptotic properties. Although there were statistically significant differences between
control and AgNP groups in the AI and the levels of active caspase 9 and active caspase 3, the level of these proteins
in GBM cells treated with AgNPs seems to be on the border between the spontaneous apoptosis and the induced. Our
results indicate that the antiproliferative properties of silver nanoparticles overwhelm proapoptotic ones. Further
research focused on the cytotoxic effect of AgNPs on tumor and normal cells should be conducted.
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Numerous complications are associated with the use of
conventional anticancer drugs, including insolubility in
water, rapid clearance, and lack of selectivity, resulting in
non-specific toxicity regarding normal cells and insuffi-
cient dose of drug delivered to the cancer cells [1].
Nanoparticles (NPs) exploit biological pathways to achieve
payload delivery to cellular and intracellular targets,
including transport across the blood-brain barrier (BBB).
The ability of these carriers to overcome BBB appears to
be enabled by receptor-mediated endocytosis through
brain endothelial cells. The possibility of employing nano-
particles for delivery of proteins and other macromole-
cules across the BBB suggests that this technology holds* Correspondence: kaja_urbanska@sggw.pl
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in any medium, provided the original work is pgreat promise for non-invasive therapy of the CNS
diseases [2], including neoplasms. Because NPs have the
affinity to acidic environment, which characterized tumor
tissue, it is believed that selective targeting strategies with
NPs facilitate more effective cancer detection and
treatment with minimized side effects to normal cells
[1]. Non-cytotoxic doses of silver nanoparticles (AgNPs)
have been recently extensively investigated due to their
capacity to induce the expression of genes associated
with impaired cell cycle progression, DNA damage, and
apoptosis in human cells [3]. According to AshaRani
and colleagues [3], AgNPs induced DNA damage
leading to cell cycle arrest in G2/M phase and enhanced
apoptosis of tumor cells, including glioblastoma
multiforme (GBM).
Most studies focused on the efficacy of anticancer
drugs in the treatment of GBM are conducted in vitro.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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by simple methodology, this experimental model has im-
portant limiting factors, related mainly to the bioavail-
ability and cell biodistribution of anticancer drugs.
Moreover, tumor cells growing in such conditions lack
the architectural and cellular complexity of in vivo tu-
mors, so it is impossible to recreate the interaction be-
tween the tumor and its host [4].
The influence of antitumor drugs on glioblastoma, as
well as other tumor, cell activity can be also investigated
in in vivo models: animal model (mice, rats) and in ovo
model. The advantages of an in ovo model compared to
animal models included simple methodology of tumor
cell implantation, economical reasons, and high survival
rate of embryos. Moreover, being naturally immunodefi-
cient, the chick embryo may accept transplantation from
various tissues and species, without immune responses.
In contrast to standard mouse models, most tumor cells
implanted on the chicken chorioallantoic membrane
(CAM) blood vessels survive without cell damage. An in
ovo model allows a rapid development and vasculariza-
tion of forming tumors. Tumors growing in an in ovo
model are visible within 2 to 5 days after tumor cell im-
plantation, compared to in vivo models, where tumors
form within 3 to 6 weeks. A possibility to conduct daily
non-invasive observations of growing tumors is also a
great advantage of this experimental model [5]. Thus, an
in ovo model can be successfully applied in oncological
studies [6]. It has been used to culture several types of
tumors and to study their growth rate, angiogenic poten-
tial, and metastatic capability [5].
Given the promising data concerning the AgNPs
utilization in anticancer therapy of CNS tumors and the
reliable utility of an in ovo model in oncological studies,
the aim of this study was to evaluate the impact of
AgNPs on proliferation and apoptosis activity of GBM
cells cultured in an in ovo model, including the levels of
active caspase 9 and active caspase 3. According to the
authors’ knowledge, no such studies have been previ-
ously conducted.Methods
Cell culture
Human glioblastoma multiforme cells, line U-87 MG
(ATCC, No HTB-14), were incubated in a Sanyo CO2
incubator (SANYO Electric Biomedical Co., Ltd, Osaka,
Japan) under standard conditions (37°C, 5% CO2, 95%
humidity), in Dulbecco’s modified Eagle’s medium (Sigma
Aldrich Chemical Co., St Louis, MO, USA) with the
addition of inactive fetal bovine serum (10% v/v) (Sigma
Aldrich) and antibiotics such as 50 U/ml of penicillin
and 50 μg/ml of streptomycin (Sigma Aldrich).
Before transplantation to chicken embryos, the cellculture was treated with trypsin/EDTA (0.25% v/v,
Sigma Aldrich). Then, cells were centrifuged (1,200 rpm/
5 min/400 g) and dispersed in culture medium in a con-
centration of 5 × 106 cells/20 μl per egg. To determine
the viability of GBM cells at the day of cell implant-
ation on CAM, trypan blue assay was used.
Chicken embryo culture
The experiments were performed on 75 fertilized chicken
eggs of Ross 308 line. The eggs were obtained from a
breeding farm ‘Drobiarstwo-działy specjalne, Lidia i
Henryk Malec’ (Dębówka, Poland). The eggs were incu-
bated in an incubator ALMD-1 N3-7 (F.H.U. Waleński,
Gostyn, Poland) with automatic egg rotation (one full
rotation per hour) at 37°C and 70% humidity.
Implantation of GBM cells on CAM of chicken eggs
The process of implantation of GBM cells was per-
formed on the sixth day of egg incubation in a laminar
hood cabinet under sterile conditions. A 0.5-cm2 hole
was cut in the egg’s shell after its cleaning with potas-
sium permanganate (Hasco Lek, Wroclaw, Poland).
The internal parchment membrane of the air chamber
was dissected, and a small silicone ring was placed on
the blood vessel area, and 5 × 106 of tumor cells sus-
pended in 20 μl drop of medium were placed into the
silicone ring. Then, the holes in the eggshell were pro-
tected by air-permeable adhesive tape (Polopor, 3 M
Vicoplast S.A., Wroclaw, Poland), and eggs were moved
back to the incubator (37°C and 70% humidity) without
rotation.
Silver nanoparticles
The hydrocolloid of nano-Ag (AgNPs) obtained from
Nano-Tech (Warsaw, Poland) was produced by an elec-
tric non-explosive patented method (patent number
US2009020364 A1) from high-purity metals (99.9999%)
and high-purity demineralized water [7]. The physical
and chemical properties of AgNPs were characterized
by Chwalibog et al. [8]. The shape and size of NPs were
inspected with a Jeol JEM-1220 transmission electron
microscope (TEM) at 80 KeV (JEOL, Tokyo, Japan),
with a Morada 11 megapixel camera (Olympus Soft
Imaging Solutions GmbH, Münster, Germany) (Figure 1).
Samples of Ag for TEM were prepared by placing droplets
of hydrocolloids onto formvar-coated copper grids (Agar
Scientific Ltd, Stansted, UK). Nanoparticles of Ag were
mostly spherical and polydispersed. The stability of the
colloidal dispersions of the nanoparticles (zeta potential)
was measured by the electrophoretic light-scattering
method with a Zetasizer Nano ZS, model ZEN3500
(Malvern Instruments, Worcestershire, UK). The zeta
potential of Ag nanoparticles was −36.4 mV, and the
Figure 1 Size distribution and TEM image of silver nanoparticles.
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were dissolved in ultra-pure water (Milli-Q water system,
Millipore Corp., Billerica, MA, USA).
Application of AgNPs and placebo solutions
On the 14th day of the eggs’ incubation, the tumors
were randomly divided into three groups: control group
(C; non-treated tumors), AgNPs group (AgNPs; tumors
treated with colloidal AgNPs), and placebo group (Pl; tu-
mors supplemented with ultra-pure water). The AgNPs
solution used in the experiment (40 μg/ml) was prepared
by diluting the AgNano stock solution (50 μg/ml) in
ultra-pure water. Concentration of AgNPs solution was
based on literature data and in vitro cytotoxic assays
(unpublished data). After dilution, AgNP solution was
incubated in bath sonication (3 cycles × 15 min) and pre-
pared freshly before use.
AgNPs solution (50 μl) was injected into each tumor,
and an additional 100 μl of solution was applied to the
tumor surface and the blood vessels adjacent to the
tumor. Similarly, in the placebo group, ultra-pure water
was used. All procedures were performed under sterileconditions with a non-pyrogenic disposable insulin syr-
inge (Polfa Lublin, S.A., Lublin, Poland).
Tumor isolation
After the 18th day of incubation, the chicken embryos
were sacrificed and the tumors were isolated. The num-
ber of isolated GBM was as follows: control group n =
20, AgNPs group n = 20, and placebo group n = 15. Each
tumor was fixed in 4% buffered formalin. In nine cases
(three tumors from each group), one part was fixed in
formalin and second was frozen at −80°C. According to
Balke and colleagues’ protocol (2010), only tumors with
a minimum 2-mm diameter and a visible area of
vascularization were taken for further analysis [9]. In the
case of a few tumors grown in one egg, the tumor with
the highest diameter located to the nearest silicone ring
was chosen for analysis.
Histological and immunohistochemical analyses
After fixation in formalin, tumors were embedded in paraf-
fin, cut into 4-μm slides, and stained by the hematoxylin-
eosin method (H&E) and immunohistochemically with
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pase 3 antibodies. All immunohistochemical procedures
were performed according to the manufacturer’s proto-
cols. Endogenous peroxidase activity was blocked by 5-
min incubation in H2O2 solution. Antigen unmasking
was performed by microwave (two cycles: 7 and 5 min,
700 W) or water bath (20 min, 98°C). Sections were
cooled for 20 min, rinsed with tris-buffered saline plus
Tween 20 (TBST) (Dako, Golstrup, Denmark), and then
incubated with primary antibody for 1 h at room
temperature or overnight at 4°C. Dako REAL™ EnVision™
Detection System, Peroxidase/DAB+, Rabbit/Mouse visua-
lization system was used for antigen detection. Details
of the primary antibodies and antigen retrieval methods
used in immunohistochemical evaluation are presented
in Table 1.Assessment of cell proliferation
Tumor cell proliferation was estimated in the sections
stained with H&E and immunohistochemically with
anti-Ki-67 antibody. The proliferative activity was esti-
mated on the basis of the mitotic index (MI) and prolif-
erative index (PI) in each specimen. MI was assessed as
the mean number of metaphase and anaphase nuclei in
ten visual fields, in triple counting (H&E, at × 400
magnification).
PI was defined as the number of Ki-67-positive GBM
cells in 103 tumors cells (at × 1,000 magnification). Mar-
ginal and necrotic areas of the tumors were excluded
from analyses.Assessment of cell apoptosis
Tumor cell apoptosis was estimated by the terminal deox-
ynucleotidyl transferase dUTP nick-end labeling (TUNEL)
method and immunohistochemically with anti-active
caspase 9 and anti-active caspase 3 antibodies. The
apoptotic activity of GBM cells was defined as the
apoptotic index (AI). Apoptotic cells were detected by
the TUNEL method with the ApopTag® Peroxidase In
Situ Apoptosis Detection Kit (Merck Millipore Head-
quarters, Billerica, MA, USA) according to the manu-
facturer’s protocol. AI was calculated as a percentage of
apoptotic cells or apoptotic bodies in 103 tumor cellTable 1 Primary antibodies and antigen retrieval methods us
Immunohistochemistry
Primary antibody Clonality Antigen unm
Ki-67, clone MIB-1 Monoclonal Microwave, ci
Active caspase 3 Polyclonal Water bath, ci
Active caspase 9 Polyclonal Microwave, ED
a1-h incubation, RT.
bOvernight incubation, 4°C.population, without marginal areas of the tumors (at ×
1,000 magnification).
Active caspase 9 (casp9I) and active caspase 3 (casp3I)
indices were defined as the percentage of positive cells
in 103 tumor cells (at × 1,000 magnification). According
to Kobayashi and colleagues [10], only tumors with
casp9I or casp3I >10.00% were considered as active
caspase-positive. Marginal and necrotic areas of the
tumors were excluded from analyses.
Western blot analysis
Total protein extraction from tumors was performed with
the tissue homogenizer X360 (Ingenierburo CAT M.
Zipperer, Staufe, Germany) at 4°C with RIPA buffer
(1×PBS, 10 ml/l Igepal CA-630, 5 g/l sodium deoxycholate,
1 g/l SDS; Sigma Aldrich) supplemented with 0.4 mM of
PMSF, 10 μg/ml of aprotinin, and 10 μg/ml of sodium
orthovanadate (Sigma Aldrich). After centrifugation
(10,000 rpm, 5 min, 300 g, 4°C), extractions were divided
into equal volumes and stored at −80°C until analysis. For
protein quantification in the whole-cell lysates, the
protein-dye-binding method of Bradford [11] with com-
mercially available reagents was used (Bio-Rad Labora-
tories, Hercules, CA, USA). An equal protein amount
(25 μg/well) was subjected to 12% SDS-PAGE electro-
phoresis at 150 V. Then, proteins were transferred at
100 V for 2 h to polyvinylidene difluoride (PVDF) mem-
branes. Further, non-specific binding was blocked via
membrane incubation with 5% non-fat dry milk in TBST
for 1 h at RT. Membranes were immunoblotted overnight
at 4°C with antibodies against active forms of caspase 9 or
caspase 3. A list of all primary and secondary antibodies
used in the Western blot method is provided in Table 2.
Next, membranes were incubated with the secondary anti-
body conjugated with HRP (Table 2). Membranes were
also probed with goat polyclonal anti-actin antibody to
normalize protein levels. The blots were developed by
the enhanced chemiluminescence (ECL) detection sys-
tem (Amersham International, Aylesbury, UK) accord-
ing to the manufacturer’s protocol. After exposure,
photographs were taken with a Kodak DC 290 zoom
digital camera and scanned and analyzed by the Kodak
EDAS 290/Kodak 1D 3.5 system. Three independent
experiments were performed for each protein.ed in immunohistochemical evaluation
asking Dilution Producer
trate buffer, pH 6.0 1:50a Dako
trate buffer, pH 6.0 1:800b Cell Signaling
TA buffer, pH 8.0 1:40a Novocastra
Table 2 Primary and secondary antibodies used in Western blot method
Western blot
Primary antibody Dilution Producer Secondary antibody Dilution Producer
Active caspase 3a 1:1,000 Cell Signaling Anti-rabbit 1:10,000 Santa Cruz
Active caspase 9a 1:1,000 Cell Signaling Anti-rabbit 1:10,000 Santa Cruz
Actina 1:200 Santa Cruz Anti-goat 1:5,000 Santa Cruz
aPolyclonal antibody.
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Statistical analyses of immunohistochemical data were
performed with Statistica 8.0 PL software, StatSoft Inc.
The results were expressed as mean ± SD, minimum, max-
imum, and median values. Continuous variables were
compared by a nonparametric Mann-Whitney U test.
Statistical significance was interpreted as highly significant
at P ≤ 0.001.
Results obtained from Western blot analysis were sta-
tistically evaluated with one-way ANOVA and Tukey’s
comparison multiple range tests with GraphPad Prism™
version 4.0 software (GraphPad Software Inc., San Diego,
USA). The results were expressed as mean ± SE, and a
value of P ≤ 0.05 was considered to be significant.
Results
The influence of AgNPs on GBM cells proliferation
Examination of GBM cells revealed that the PI in con-
trol untreated tumors ranged from 21.00 to 36.00% with
a mean of 28.72% ± 0.85% (Figure 2A), which was in
agreement with the results obtained for the placebo
group. In the placebo group, Ki-67+ cells ranged from
21.40 to 35.70% (with a mean of 27.29% ± 0.89%). In the
AgNPs-treated group, the PI index was significantly lower
(P ≤ 0.001) compared to the control and placebo groups
and ranged from 13.70 to 31.00% (mean 20.93% ± 0.69%)
(Figure 2B). In the control group, MI ranged from 4.10 to
12.20 (mean 8.54 ± 0.48). In the placebo group, the percent-
age of GBM cells in metaphase and anaphase was 5.25 to
11.23 (mean 7.89 ± 0.36), comparable to the results for the
tumors from the control group. The MI of tumors from
the AgNPs group ranged from 1.90 to 10.83 (mean 5.62 ±
0.43). All changes caused by AgNPs administration led to
a significant reduction of GBM cells in the M phase
compared with cells from control and placebo groups
(P ≤ 0.001). Results of MI and PI mean values of all groups
are summarized in Figure 3.
The influence of AgNPs on GBM cells apoptosis
The administration of AgNPs did not induce cell
apoptosis; however, the AI values, as well as casp9I and
casp3I, were significantly higher in the AgNPs-treated tu-
mors. AI in the control group ranged from 0.8 to 2.30%
(mean 1.12% ± 0.09%) (Figure 2C) and was fit into the
values of the spontaneous apoptosis intensity rate. In theplacebo group, the number of positive stained cells was
similar and ranged from 0.60 to 1.30% (mean 1.07% ±
0.05%). In the AgNPs group, the AI values were also
within the spontaneous apoptosis values and ranged
from 1.40 to 3.30% (Figure 2D). However, the mean AI
value (2.02% ± 0.12%) obtained for this group was statis-
tically higher (P ≤ 0.001) than in control and placebo
groups.
Activation of apoptosis was confirmed by the detection
of active caspase 9 and active caspase 3 level via immu-
nohistochemistry and Western blot. Immunohistochemi-
cal analysis showed cytoplasmic expression of active
caspase 9 with moderate staining intensity. Casp9I was
low, independently from the experimental group. Immu-
nohistochemical study showed that all cases from the
control group were considered as active caspase 9 nega-
tive (Figure 2E). The percentage of active caspase 9+
cells ranged from 4.90 to 9.80% (mean 6.64% ± 0.30%).
Similar results were obtained in the placebo group, with
the exception of one tumor with more than 10% of cas-
pase 9-positive cells (casp9I was from 2.80 to 10.80%
with the mean 6.14 ± 0.49). After AgNPs treatment, the
percentage of caspase 9+ cells significantly increased
(P ≤ 0.001) and ranged from 4.90 to 12.30% (Figure 2F).
However, mean casp9I was only 9.13 ± 0.48.
Western blot analysis confirmed that the level of active
caspase 9 expression was higher in AgNPs-treated and
placebo groups than in the control group; however, the
differences were not statistically significant (P ≤ 0.05,
Figure 4).
The intensity of anti-active caspase 3 immunolabeling
was stronger than with anti-caspase 9 antibody. Results
obtained from immunochemical analysis of the presence
of active caspase 3 were in agreement with those
described for active caspase 9. In the control group, the
percentage of active caspase 3+ cells (Figure 2G) was
similar to the placebo group (Figure 2H) (2.80 to 11.30%,
mean 5.65% ± 0.55%, and 3.40 to 11.30%, mean 6.07 ±
0.61, respectively). In the AgNPs group, casp3I was 5.50
to 19.50% (Figure 2H). The statistical analysis showed
that the mean number of casp3I in the AgNPs group
(10.46% ± 0.88%) was higher than in others (P ≤ 0.001),
as shown in Figure 4. However, the lower limits of
casp3I in AgNPs-treated tumors were similar to those





Figure 2 The influence of AgNPs on GBM cells proliferation and apoptosis indices. Ki-67 expression in GBM cells from control group (A)
and from GBM cells treated with AgNPs (B). Apoptotic cells in GBM from control group (C) and from GBM treated with AgNPs (D). Active caspase
9 expression in GBM cells from control group (E) and from GBM cells treated with AgNPs (F). Active caspase 3 expression in GBM cells from con-
trol group (G) and from GBM cells treated with AgNPs (H), bar = 10 μm.
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to increase in AgNPs-treated tumors compared with
other groups and the difference was statistically signifi-
cant (P ≤ 0.05, Figure 5).
Results of AI, casp9I, and casp3I mean values of all
groups are summarized in Figure 3. The detailed immu-
nohistochemical and histological results for control, pla-
cebo, and AgNPs groups are given in Additional file 1:
Tables S1, S2, and S3 (see in Additional file 1),
respectively.
Discussion
Nanoparticles are attractive material for medical pur-
poses because of their unique features, including largesurface to mass ratio. A relatively large (functional) sur-
face is able to bind, adsorb, and carry other compounds
such as drugs, probes, and proteins, e.g., ligands, which
recognize receptors of the target cells [12]. Due to the
slightly acidic pH of tumor cells, the release of silver
ions from AgNPs is higher in tumor cells compared to
normal cells. Thus, NPs can help enhance the accumula-
tion of drug within the tumor while limiting accumula-
tion in healthy organs. AgNPs loaded with different
chemotherapeutic drugs induce selective toxicity and en-
hance efficacy of anticancer drugs, which enable to re-
duce their dosage [13]. Additionally, NPs modulate
cellular and humoral immune responses. Recently, some
studies in rodents have examined the NPs distribution,
Figure 3 Comparing mean values of all immunohistochemically/histologically examined parameters in tumors from control, placebo,
and AgNPs groups. Letters (a, b) mean highly statistically significant differences, P ≤ 0.001.
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found that NPs with a diameter greater than 100 to
150 nm tend to accumulate in tumors because of their
higher extravasation in comparison with normal vascula-
ture [14-16].Figure 4 The level of active caspase 9 in GBM cells cultured in an in o
GBM cells from control group (C), placebo group (Pl), and AgNPs group (A
OD) obtained for the different bands, expressed in relative terms, defined a
9 and OD values obtained for actin band. Letters (a, a) mean no statistically
three independent experiments.The cytostatic effect of silver on cancer cells is the re-
sult of the active physico-chemical interaction of silver
atoms with the functional groups of intracellular pro-
teins as well as nitrogen bases and phosphate groups of
DNA [17]. In our study, AgNPs administration caused avo model. (A) Western blot analysis of the level of active caspase 9 in
gNPs). (B) Graph showing the optical density values (optical density,
s the ratio of OD values obtained for band representing active caspase
significant differences, P ≤ 0.05. The obtained results are the mean of
Figure 5 The level of active caspase 3 in GBM cells cultured in an in ovo model. (A) Western blot analysis of the level of active caspase 3 in
GBM cells from control group (C), placebo group (Pl), and AgNPs group (AgNPs). (B) Graph showing the optical density values (optical density,
OD) obtained for the different bands, expressed in relative terms, defined as the ratio of OD values obtained for band representing active caspase
3 and OD values obtained for actin band. Letters (a, b) mean highly statistically significant differences, P≤ 0.05. The obtained results are the mean
of three independent experiments.
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examined proliferation indices (PI and MI) were signifi-
cantly lower in the AgNPs group in comparison with
control and placebo groups. The PI values of tumors
treated by AgNPs were similar to glioblastoma multi-
forme with long-term survival (6.00 to 20.00%) [18], and
the most often diagnosed spontaneous GBM, which
causes death within less than 1 year, has higher PI
values: 25.00% to 30.00% [19,20]. Values obtained for
spontaneous glioblastoma correspond to the PI we ob-
tained for control and placebo groups. The lower values
of examined proliferation markers may be a result of
AgNPs accumulation in the nucleus of GBM cells, where
it causes chromosome instability and mitotic arrest.
Hence, tumor cells cease to proliferate [3]. Another ex-
planation of AgNP-mediated inhibition of cell division
could be AgNPs’ interaction with structure and func-
tions of actin cytoskeleton, involved in cell division sig-
naling cascades [3]. Results obtained in our study
confirm the antiproliferative properties of AgNPs in
GBM cells and show that AgNPs could possess potential
benefits in terms of the anticancer treatment of GBM
patients (related to prolongation of overall survival) as
similar observations were published previously [3,21,22].
Lara-González and colleagues [22] discovered that theadministration of AgNPs to tumor-bearing mice at the
time of tumor injection caused significantly increased
survival, compared with controls. This effect was more
potent than after vincristine treatment.
The intensity of apoptosis also has a major impact on
tumor growth. Studies have revealed a high frequency of
apoptosis in spontaneously regressing tumors and tu-
mors treated with cytotoxic agents. Thus, the estimation
of apoptosis in tumor cells (AI), together with PI, is an
important marker of tumor development and has prog-
nostic significance [23]. There is a wide variation in the
extent of spontaneous apoptosis not only between differ-
ent tumor types but also within in a given tumor type.
The spontaneous AI, in GBM and other tumors, mea-
sured by the TUNEL method, does not exceed 10.00% in
any of them [24].
In our study, the mean AI of GBM cells cultured in
ovo, in control, and placebo groups was 1.12% and
1.07%, respectively. Results obtained for any experimen-
tal group were within the limits for spontaneous GBM
presented by other authors, who estimated the number
of apoptotic cells in GBM patients as less than 1.50%
and even 0.00% in some GBM cases [25]. Apoptosis is
also particularly important for the development of effect-
iveness of anticancer drugs as they restore the ability of
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sensitivity of neoplasm cells [26]. A large number of stim-
uli, including various chemotherapeutic agents, ultra-
violet and γ-irradiation, heat, osmotic imbalance, high
calcium concentration, and nitrogen oxide can induce
apoptosis [24]. There is some information about the in-
duction of apoptosis by AgNPs [26,27]. Proapoptotic
properties of AgNPs were also verified in our study.
Further studies are, however, needed.
Our results showed that AgNPs administration caused
a statistically significant increase of GBM AI values. This
effect could result from the generation of reactive oxy-
gen species (ROS) by AgNPs. The active surface of
AgNPs can directly induce the generation of original free
radicals, and the dissolution of AgNPs into Ag ions. It
caused damage to DNA and disruption of mitochondrial
membrane potential, released cytochrome c, and led to
mitochondrial-dependent apoptosis [3,28,29]. Although
AgNPs administration caused a statistically significant
increase in apoptosis, all obtained results of tumors from
the AgNPs group are in agreement with the results for
apoptosis in spontaneous GBM, which was at the level
of <3.00% [30-33]. It is well known that malignant tumor
cells, such as GBM, are extremely resistant to apoptosis
and particularly resistant to radiation and chemotherapy.
It can be explained by low levels of spontaneous apop-
tosis, which might correlate with enhanced resistance to
cytotoxic treatment strategies [34]. This may explain the
slight increase of AI values in GBM treated with AgNPs
compared with the control group (2.02% vs. 1.12%).
Results of the other study have shown that the proa-
poptotic effect of silver nanoparticles can be achieved by
its repetitious administration [22]. Our observations sug-
gest that during single AgNPs administration, the higher
AgNPs concentration could potentially enhance their
proapoptotic effect. Finally, AgNPs could be conjugated
with chemotherapeutic agents used in GBM treatment,
which allow a lower dose of the anticancer drugs and
minimize the cytotoxic influence on normal cells.
There is only one publication about the immunohisto-
chemical characterization of caspase level in spontan-
eous GBM. Bodey and colleagues [35] estimated the
percentage of casp 9+ in tumor cells at the level of 10%,
which is consistent with the results presented in our
study (mean value of casp9I was 6.64%, 6.14%, and
9.13% in control, placebo, and AgNPs groups, respect-
ively). Bodey and colleagues [35] assessed the staining
intensity as very strong to strong. In our study, immuno-
histochemical analysis showed that the expression of
caspase 9 in control and placebo tumors was comparable
and the staining intensity was from strong to weak, and
only in one case in the placebo group was casp9I consid-
ered as positive. Several mechanisms blocking the activa-
tion of apoptotic pathways, including caspase 9 activationblocking, have been postulated in GBM cells, which could
explain the low level of this protein in GBM [36,37]. These
hypotheses seem to be confirmed in our studies, where
low casp9I values were obtained for all analyzed tumors.
Low expression of caspase 9 was confirmed also by
Zarnescu and colleagues [38], who estimated the expres-
sion of caspase 9 in U-87 glioblastoma xenografts. Cas-
pase 9 overexpression and its activation lead to apoptosis.
Since the majority of anticancer strategies initiate apop-
tosis through caspase 9 activation, the modulation of cas-
pase 9 expression may be exploited by designing new
ways to control apoptosis in malignant tumors, including
GBM [39]. There are a lot of publications about the inter-
actions between different types of nanoparticles and
tumor cells which have shown that titanium dioxide nano-
particles as well as curcumin-loaded nanoparticles cause
intrinsic-mediated apoptosis in human cells and that cas-
pase 9 plays a critical role in this process [40,41]. However,
none of these publications focused on the activation of
caspase 9 in GBM. In our study, the level of active caspase
9 protein in control GBM was very low. AgNPs caused an
increase of active caspase 9 expression in GBM cells. The
majority of cases defined as positive were found in just
this group. It seems that NPs could significantly contrib-
ute to the development of new approaches of drug deliv-
ery in cancer and provide a platform for combined
therapeutics with subsequent monitoring of response [42].
However, this hypothesis requires more extensive studies.
Apart from caspase 9, which is an initiator caspase,
the most important role in the apoptosis pathway acti-
vation is played by caspase 3, an executioner caspase.
Caspase 3 is expressed in normal and neoplastically
transformed human cells; however, the expression of
this caspase in CNS neurons is low or is not detected at
all [35]. The level of the active form of caspase 3 has
been examined in many types of cancer in correlation
with its histological grade of malignancy and may be
used as a prognostic marker of the patient’s overall sur-
vival [43]. In our study, caspase 3 has been shown in
the cytoplasmic staining pattern; however, a tendency
to translocation from the cytoplasm to the cell nuclei
may occur [35]. Schiffer and colleagues [33] showed
positive staining of active caspase 3 in nuclei, cyto-
plasms, or in both cell compartments [33]. The per-
centage of GBM cells with positive nuclear reactions
can reach 10% of all tumor cells [35]. Some regulators
of DNA metabolism can be activated by caspase 3,
which subsequently translocates to the nucleus [33].
Apart from the fact that the presence of active caspase-
3 in the nucleus starts the execution phase of apoptosis,
such localization may affect the evasion of the immune
system by the tumor cells [35].
There are large divergences in casp3I values in spontan-
eous GBM. In some studies, the percentage of caspase 3+
Urbańska et al. Nanoscale Research Letters  (2015) 10:98 Page 10 of 11cells ranges from 7.36 to 59.52% (mean 17.67%) [44],
whereas in other cases it ranges from 0.70 to 71.60%
(mean 32.60%) [45]. In our study, the immunohistochemi-
cal staining and densitometric analysis of electrophero-
grams of Western blot have shown that the expression of
the active form of caspase 3 in control and placebo groups
were lower than in the AgNPs group. However, the mean
value of casp3I in tumors treated with AgNPs was still
much lower compared with the spontaneous glioblast-
omas, 50.00% [35], even in the AgNPs group. However,
the methodology used by the cited authors differs from
that presented in our work. Results obtained by Bodey
and colleagues [35] were determined by estimation. Tira-
pelli and colleagues [44] counted the casp 3+ cells in two
visual fields per slide with the highest number of positively
staining cells. Kobayashi and colleagues [10] counted posi-
tive cells in a population of 500 cells, and in our study,
1,000 cells from each specimen were counted. Results ob-
tained by other authors indicate that in GBM cells, the
fraction of casp 3+ cells is too low to activate the apoptotic
program [45].
In our study, the value of casp3I significantly increased
after AgNPs treatment of GBM cells, which was con-
firmed immunohistochemically and by the Western blot
method. It may indicate, according to Piao and colleagues
[29], that AgNPs have the power to induce cell death
through the activation of caspase-dependent pathways.
The same results obtained by Gurunathan and colleagues
[46] showed that during treatment of MDA-MB-231 cells
with AgNPs, the level of caspase 3 increased to a level
comparable with that of caspase-3 activation [46]. It was
also confirmed by Satapathy and colleagues [47]. One of
the reasons for the death of cancer cells with AgNPs is the
release of silver ions from NPs. The generation of silver
ions from AgNPs is the main culprit in terms of the for-
mation of oxidative stress that activates caspase 3 [48].
Conclusions
The results of our study indicate that AgNPs can influence
biological activity of U-87 cells (defined as their prolifera-
tive and apoptotic indices). AgNPs inhibit proliferation of
GBM cells and have proapoptotic properties. However,
the level of active caspase 3 and active caspase 9 in GBM
cells after AgNPs treatment seems to be on the border be-
tween spontaneous and induced apoptosis. For these rea-
sons, research focused on the effects of AgNPs on the
proliferation and apoptotic activity of GBM should be
continued.
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